A new study published in the Journal of Clinical Psychopharmacology has found that nearly 16% of men aged 40 to 85 who used Risperdal developed gynecomastia, or male breast tissue, within 2 months. Risperdal (generically named risperdone) is an antipsychotic drug with more than 12 million prescriptions in the United States ever year.
The study involved more than 82,800 respondents and more than 8,000 cases of gynecomastia. Researchers also found that men who used risperdone were more likely to develop breast tissue than men who used other antipsychotics.
Risperdal has also been linked to an increased risk of breast tissue growth in male adolescents and boys. Multiple Risperdal lawsuits have been filed against manufacturer Janssen Pharmaceuticals alleging the company knew of the increased risks of gynecomastia associated with Risperdal but failed to warn doctors and patients.